1. Home
  2. Analysis
  3. Zometa
  4. Zepzelca

Zometa and Zepzelca drug interactions - a phase IV clinical study of FDA data

Summary:

The phase IV clinical study analyzes what interactions people have when they take Zometa and Zepzelca. It is created by eHealthMe based on reports of 4 people who take the same drugs from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Zepzelca?

Zepzelca has active ingredients of lurbinectedin. eHealthMe is studying from 488 Zepzelca users. Check the latest studies of Zepzelca.

On May, 23, 2026

4 people who take Zometa and Zepzelca together, and have interactions are studied.

Zometa and Zepzelca drug interactions.

What are the common drug interactions of Zometa and Zepzelca, by gender? *:

female:

  1. Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
  2. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  3. Neuroendocrine tumour (a tumour that forms from cells that release hormones into the blood in response to a signal from the nervous system)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Respiratory failure (inadequate gas exchange by the respiratory system)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)

male:

n/a

What are the common drug interactions of Zometa and Zepzelca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
  2. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  3. Neuroendocrine tumour (a tumour that forms from cells that release hormones into the blood in response to a signal from the nervous system)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Respiratory failure (inadequate gas exchange by the respiratory system)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)

40-49:

n/a

50-59:

n/a

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and Zepzelca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Zometa and Zepzelca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zometa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zepzelca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zometa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zepzelca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid and lurbinectedin (the active ingredients of Zometa and Zepzelca, respectively), and Zometa and Zepzelca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.